MicroRNA-302a-3p suppresses hepatocellular carcinoma progression by inhibiting proliferation and invasion
Authors Ye Y, Song Y, Zhuang J, Wang G, Ni J, Zhang S, Xia W
Received 3 March 2018
Accepted for publication 23 May 2018
Published 10 December 2018 Volume 2018:11 Pages 8175—8184
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
Ying Ye,1,* Yanan Song,1,* Juhua Zhuang,1 Guoyu Wang,1 Jing Ni,1 Suiliang Zhang,2 Wei Xia1
1Department of Nuclear Medicine, The Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Oncology Department, The Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Background: Involvement of microRNAs in tumor development and their potential as prognostic biomarkers had been well acknowledged. However, the expression, clinical significance, and functional mechanisms of microRNA (miR)-302a-3p in hepatocellular carcinoma (HCC) have not been reported.
Patients and methods: Real-time quantitative polymerase chain reaction was used to evaluate the expression of miR-302a-3p in 111 HCC tissues and adjacent normal liver tissues. Its association with clinicopathological characteristics was analyzed by the chi-square test. The Kaplan–Meier univariate survival analysis and multivariate Cox regression analysis were used to identify the clinical significance of miR-302a-3p in the overall survival (OS) of HCC patients. Transfection of miR-302a-3p mimics into HepG2 and Huh7 HCC cell lines was conducted to reveal its underlying mechanism in regulating HCC progression.
Results: miR-302a-3p expression was significantly decreased in HCC tissues compared with that in paired adjacent normal liver tissues (P=0.005). miR-302a-3p expression was correlated with tumor number (P=0.003), tumor size (P<0.001), and tumor TNM stage (P=0.028). The Kaplan–Meier survival analysis showed that patients in the high miR-302a-3p expression group had a better OS than those in the low miR-302a-3p expression group (P=0.002). Multivariate analysis confirmed that miR-302a-3p expression can be used as an independent predictor for HCC prognosis (HR=0.480, 95% CI=0.249–0.894, P=0.039). Proliferation, migration, and invasion capacities were all decreased in cells transfected with miR-302a-3p mimics. Moreover, our data showed a direct effect of miR302a-3p on inhibiting the expression and signaling of PRKACB in HCC cells.
Conclusions: miR-302a-3p serves as a tumor suppressor in HCC progression by directly inhibiting tumor proliferation and invasion, and its low expression is a potential biomarker for predicting a poor prognosis of HCC patients.
Keywords: hepatocellular carcinoma, miR-302a-3p, invasion, prognosis, proliferation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]